GLP-1 RAs for type 2 diabetes significantly lower one-year mortality, especially in those also diagnosed with obstructive sleep apnea.

The FDA will complete the approval process for certain medications in 1 to 2 months, a change from the usual 10-month review.

Low-carbohydrate diets, especially ones focused on animal-based protein and fat, were overall associated with an increased risk for type 2 diabetes.

Smoking cessation increased overall survival in cancer survivors who smoked, regardless of disease stage, compared with current smoking.

A diagnosis of distant breast, colorectal, or non-small cell cancer was less likely among individuals receiving housing assistance than among matched control individuals, compared to a localized ...

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

California will start selling a generic version of glargine at a recommended price of $11 per pen, or $55 for a five-pack, January 1.

Prior authorizations affect 74% of people with cancer, of whom half reported that the health care teams fully handled it.

Nearly 700 medicines used in the US to treat common conditions contain at least 1 chemical sourced only in China.

Obeticholic acid added to ursodeoxycholic acid improved alkaline phosphatase and bilirubin levels among patients with PBC unresponsive to first-line therapy.

Achieving sustained virological response after direct-acting antiviral therapy reduces liver-related events among those with decompensated HCV cirrhosis.

New code E11.A applies to patients who use lifestyle interventions to show no signs of type 2 diabetes for at least 3 months.